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ABSTRACT
Bacteria from the genus Streptomyces are
very important for the production of natural bio-
active compounds such as antibiotic, antitumour
or immunosuppressant drugs. Around two-thirds
of all known natural antibiotics are produced by
these bacteria. An enormous quantity of crucial
data related to this genus has been generated
and published, but so far no freely available
and comprehensive database exists. Here, we
present StreptomeDB (http://www.pharmaceutical-
bioinformatics.de/streptomedb/). To the best of
our knowledge, this is the largest database of
natural products isolated from Streptomyces. It
contains >2400 unique and diverse compounds
from >1900 different Streptomyces strains
and substrains. In addition to names and molecular
structures of the compounds, information about
source organisms, references, biological role,
activities and synthesis routes (e.g. polyketide
synthase derived and non-ribosomal peptides
derived) is included. Data can be accessed
through queries on compound names, chemical
structures or organisms. Extraction from the litera-
ture was performed through automatic text mining
of thousands of articles from PubMed, followed by
manual curation. All annotated compound struc-
tures can be downloaded from the website and
applied for in silico screenings for identifying new
active molecules with undiscovered properties.
INTRODUCTION
Streptomyces, a well-studied genus of Gram-positive
bacteria, belongs to the phylum Actinobacteria. These
bacteria present a strikingly similar lifestyle to that of
ﬁlamentous fungi and, like those, most streptomycetes
live as saprophytes in the soil. They also successfully
inhabit a wide range of other terrestrial and aquatic
niches, and some strains are plant and animal pathogens
(1). About 500 different species and thousands of strains
and isolates are described in the literature (2,3), account-
ing for an extremely diverse pool of secondary metabolites
produced from several synthesis routes. In fact, almost
half of all known natural products (NPs) are produced
by ‘actinomycetes’ (mainly Streptomyces) (1,4). Even
though these soil-dwelling organisms are better known
as antibiotic producers—over two-thirds of the clinically
useful antibiotics are isolated from Streptomyces (5)—the
secondary metabolites have a wide bioactive and thera-
peutic spectrum. Approved antitumour drugs such as the
anthracycline antibiotic daunorubicin or the bleomycin
complex, and autoimmune active agents such as the
macrolide tacrolimus, among many others, are NPs exclu-
sively produced by Streptomyces. Both novel and rare
chemical scaffolds with therapeutically relevant activities
have been discovered (6–8), like the unprecedented C-5
spirocyclic fusion found in the antitumour fredericamycin
A or the unique cyclohexa-1,2,4-triketone moiety
of fredericamycin E (9). Genetic manipulation of
Streptomyces has been used to generate highly diverse
chemical libraries by modiﬁcation of synthesis routes
(10–13). Altogether, these facts highlight the renewed
interest from academia and the pharmaceutical industry
in exploring NP libraries for compounds with novel scaf-
folds showing therapeutic activity (14).
Here, we present StreptomeDB, a database of com-
pounds isolated from Streptomyces spp. The information
included was collected from text mining and manual
curation of thousands of abstracts and full papers using
a newly developed in-house platform and two external
databases. StreptomeDB contains data regarding the
producing strains, the synthesized compounds, their bio-
logical activity and the synthesis route, if available. It also
features citations to scientiﬁc literature and the chemical
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structure and physico-chemical properties of the
compounds. To the best of our knowledge, it is the
largest compilation of NPs produced by Streptomyces
spp., including annotations on activities (e.g. antibiotic,
antitumour or antifungal) and synthesis routes
(e.g. polyketide synthase (PKS)-, non-ribosomal peptide
synthase (NRPS)- or terpene-derived compounds). The
database can be accessed by producer name, compound
name, similarity and substructure chemical queries, biolo-
gical activity and synthesis route annotation.
Furthermore, it features a ‘most common substructure se-
lection’ (MCSS) panel containing the most frequent
occurring substructures within the available chemical
space, allowing for the fast and efﬁcient selection of
compound families (e.g. b-lactams and tetracyclines).
StreptomeDB brings a unique tool to researchers in
both academia and the pharmaceutical industry for the
study of secondary metabolites and the discovery of thera-
peutically relevant novel compounds from natural
sources. To facilitate the use of the compounds in
in silico screenings for the identiﬁcation of new active
molecules, all structures including their annotations can
be downloaded from the website as a structure data ﬁle.
The database is freely accessible at http://www.
pharmaceutical-bioinformatics.de/streptomedb.
DATA AND METHODS
Extraction of information in abstracts
All articles available in PubMed were searched for the
term ‘streptomyces’ in medical subject heading (MeSH)
terms, keywords, titles and abstracts. For the resulting
articles, the abstracts were screened for potential
compound names using the CIL database (15), yielding
around 15 600 abstracts which potentially contained infor-
mation on compounds produced by Streptomyces spp. A
team of seven experts in the ﬁeld of streptomycetes, their
products and the mode of action of antibiotics from
biology, chemistry, bioinformatics and pharmaceutical
sciences were reading and annotating over 8400 abstracts
(including all abstracts of the last 3 years) using full texts if
needed with an in-house software module. Texts were
searched for the following types of entities: compounds,
producing organisms, activities of the compound and the
synthesis pathways. The latter were deﬁned as part of or
gene cluster for certain pathways speciﬁc for the synthesis
of secondary metabolites such as antibiotics. This included
terpene, shikimate, ribosomal peptide synthetases (RPSs),
NRPSs and PKSs pathways.
Identical test sets containing 10 abstracts were used in
the beginning to compare and adjust the curation attitude
and reliability of the different curators in three rounds
with subsequent reﬁnements of entity deﬁnitions, resulting
in ﬁxed and mandatory guidelines for curation. Unique
identiﬁers were assigned to the terms of the annotated
entities. For most compounds, structural descriptions
were inherited from the PubChem database if available
or drawn. Organism names were uniﬁed and organized
in a ‘main organism’ and ‘strains/mutant’ hierarchy.
Activities and synthesis routes were stored with the
annotated text parts and additionally classiﬁed by
keywords.
Curation work yielded around 5700 abstracts and full
texts containing information on Streptomyces spp.
producing one or more compounds and describing
compound activities or synthesis routes. All remaining
articles contained no such information in the abstracts
or available full texts. In 2250 annotated abstracts,
compound and organism names did not allow for the as-
signment of unique identiﬁers. Thus, they are subject to
on-going curation.
Inclusion of data from existing data sources
To complete, enlarge and conﬁrm the body of available
information in StreptomeDB, existing data sources with
new and overlapping data were used: the thesaurus of the
MeSH, the KNApSAcK database (16) and the Novel
Antibiotics DataBase (NADB) (http://www0.nih.go.jp/
jun/NADB/search.html), containing substances ﬁrst
reported in the Journal of Antibiotics (http://www.anti
biotics.or.jp/journal/ja-top.htm). Descriptions of MeSH
were queried for compounds with descriptions specifying
an organism which could be uniquely identiﬁed. In MeSH
descriptions, 83 compound–organism relationships could
be found and unique identiﬁers for compounds and organ-
isms were assigned. Data from the NADB are available
through its ‘Namazu: a full text search engine’ interface
(http://www0.nih.go.jp/jun/NADB/namazu.cgi?query=
streptomyces, accessed 25 July 2012). It provided 2557
abstracts of which 1225 unique identiﬁers could be as-
signed to compounds and organisms. The KNApSAcK
database contains 1988 metabolite–Streptomyces spp.
relationships with one or more associated literature
references (http://kanaya.naist.jp/knapsack_jsp/result.jsp?
sname=organism&word=streptomyces, accessed 25 July
2012). For 1245 of those compound–organism references,
unique identiﬁers for compounds and organisms could be
assigned.
Failure of assignment of unique identiﬁers
Failure of assignment of unique identiﬁers to compound
and organism names in the three existing data sources and
the curated abstracts was caused by ambiguous names,
spelling and curation errors which could not be traced
back, or compound names and synonyms which were
not available in PubChem or any other freely accessible
database.
Searching with most common substructures
To enable the user to search with common substructures,
all compounds were fragmented using the RECAP
algorithm (17). The 120 most frequent fragments contain-
ing a cyclic structure occurring as substructures in all
StreptomeDB compounds are presented to the user for
selection.
Data were stored in a PostgreSQL database
(PostgreSQL 8.4.8, PostgreSQL Global Development
Group). All calculations of chemical properties were
executed using Open Babel 2.3.0 (18).












The database contains >2400 different secondary metab-
olites produced by Streptomyces spp. (Table 1). Diverse
compound classes such as anthracyclines and cyclic
peptides are included (Figure 1). The large proportion of
very complex compounds results in a much higher average
molecular weight (median: 453 g/mol) compared with
typical drugs (median: 310 g/mol, 19). For example, the
approved antibiotic drug actinomycin has a molecular
weight of 1255 g/mol.
The MCSS panel for compound selection (Figure 2) is
based on substructures that can be synthetically combined
and are common in drug-like molecules. The panel high-
lights the large diversity of the rings present in the NPs of
StreptomeDB (Figure 1). For example, 60 b-lactam anti-
biotics and 50 antitumour anthracyclines are included in
the database (20). The MCSS panel allows a direct selec-
tion and identiﬁcation of compounds containing such
substructures.
Activities and synthesis routes
Many pharmaceutically relevant peptides are synthesized
by NRPSs (21). Such compounds are characterized by an
extremely broad range of biological activities, pharmaco-
logical properties and rare structural features. NRPS-
derived compounds annotated in StreptomeDB include
cytostatic agents such as epothilone or bleomycin, or anti-
biotics such as daptomycin or enduracidin. For other
compounds of that class, the broad range of activities
has not been clariﬁed yet and remains subject to further
research (22).
The 217 compounds annotated as PKSs derived are the
largest group of StreptomeDB. Analogous to NRPS-
derived compounds, they are an important source for
pharmacologically relevant molecules (23). Many of the
therapeutically used antibiotics, such as tetracyclines are
produced by PKS. Examples of important polyketides
included in StreptomeDB with annotated activity are
the antibacterial oxytetracycline and the anticancer
geldanamycin (24). Additional synthesis routes include
terpene synthesis or RPS.
For 875 NPs, activity information is included in the
database. The annotations contain very speciﬁc descrip-
tions (e.g. inhibitor of protein X) as well as more unspe-
ciﬁc classiﬁcations (e.g. antibiotic). In total, 71 different
activity classiﬁcations have been included in the database.
Case studies
The database enables fast delivery of information related
to research in pharmaceutical sciences or chemistry.
Some examples for possible applications are explained in
the following.
Drug discovery
Many NPs have therapeutically relevant activities (25). To
start a general search for bioactive compounds, it is useful
to have a deeper look on substructures known to be active
and which appear in several drugs (26). For example,
phenazine compounds possess activities on several target
proteins because of their ability to promote electron
transfer (27). Particularly, the effect on G-protein-
coupled receptors (GPCRs) is demonstrated by several
phenazine-containing drugs (28).
StreptomeDB contains 26 phenazines. Structures can be
easily selected through the MCSS panel (Figure 2).
Assaying the activities of NPs on GPCRs or other
known drug targets may reveal some new speciﬁc thera-
peutic functions. Recently, Ohlendorf et al. (29) could
show that the phenazine geranylphenazinediol extracted
from a marine Streptomyces spp. is a potent inhibitor of
the human acetyl-cholinesterase.
Search for enzymes able to catalyse speciﬁc
synthesis steps
Aziridine-containing NPs are extremely rare (30).
However, the DNA alkylating and crosslinking activities
of aziridine analogues have been shown to be attractive
for the development of anti-leukaemia therapeutics (31).
The knowledge about the organisms, gene clusters and
enzymes that can synthesize such ring systems may
enable the design of chemotherapeutic agents with
enhanced stability and tumour selectivity which can be
produced by genetically modiﬁed enzymes (30).
A substructure search in StreptomeDB starting with
aziridine results in 13 compounds containing this func-
tional group (Figure 3). The related links lead to the
producing organisms and to the source publications.
Speciﬁcally, Zhao et al. (32) describe a PKS-gene cluster
which is involved in the pathway for the synthesis of
azinomycin B. This is a very good starting point for the
identiﬁcation of associated genes and the investigation of
the enzymatic mechanism responsible for building import-
ant groups such as aziridine rings.
Search for antibiotics effective against newly
resistant bacteria
Overtreatment with antibiotics has led to bacterial strains
resistant against several known antibiotics (33). Yet, no
longer used antibiotics have been successfully adminis-
tered in the treatment of therapeutic infections caused
by resistant bacteria (34).
In StreptomeDB, many antibiotics are described which
were never or rarely used as clinical drugs. An activity
Table 1. Content of StreptomeDB (accessed 9 October 2012)
Compounds (No.) 2444 Annotated PKS-synthesized compounds (No.) 256
Molecular weight [g/mol] (median) 452.5 Annotated NRPS-synthesized compounds (No.) 51
Compounds that ﬁt to the Lipinski’s Rule of Five (No.) 1522 Different organisms, including strains (No.) 1985
Compounds annotated with activity (No.) 1036 Referenced articles (No.) 4544
Compounds annotated with structure (No.) 2444 Number of compound–organism relationships (No.) 4341










search in the database starting with ‘antibiotic’ results in a
list of described antibiotics with the related publications.
Antibiotics described long ago such as fosfomycin or
chloramphenicol may be still active against highly resist-
ant strains when administered either on their own or in
combination with other antibiotics (35,36).
DISCUSSION AND FUTURE PROSPECTS
Different statements exist about the total number of NPs
which are synthesized by Streptomyces spp. Some years
ago, Be´rdy (4) reported a number of 3000 bioactivities
but the referenced source database is no longer available
and it remains unclear which compounds are meant.
KNApSAcK and NADB databases list 1500 compounds
which are synthesized by Streptomyces. StreptomeDB has
currently annotated around 2400 unique compounds but
the number is continuously increasing. One reason for not
including all compounds that are described is that import-
ant information is included in the full texts but is not ne-
cessarily in the abstracts of articles. The detailed analysis
of related full texts is subject to an on-going project which
will further increase the dataset not only for compounds
but also for activity data and synthesis routes. Newly
published articles are curated and included to the
database on a three-monthly basis.
Furthermore, several hundreds of compounds
annotated in StreptomeDB were not included in the
PubChem database and therefore could not be assigned
easily with structures. Since we have started to draw many
of those compounds manually, the assignment of all of
them with chemical structures is intended.
The interest of researchers in genomic data encoding for
synthesizing enzymes of NPs is of growing interest.
Knowledge about the enzymatic mechanisms of important
synthesis steps enables the production of chemicals which
can be produced in engineered organisms (10–13).
Databases describing genes and gene clusters encoding
for important enzymes involved in pathways for the pro-
duction of NPs exist [e.g. NORINE (22) and NRPS-PKS
(37)] but a lot of important data are still hidden in publi-
cations as text information. StreptomeDB complements
existing datasets and supports data collection projects
dealing with biological chemistry by allowing recognition
of organisms containing enzymes which are able to
catalyse important functional groups and speciﬁc synthe-
sis steps. More detailed information about involved
pathways and related genes responsible for compound
Figure 1. Examples of NPs produced by Streptomyces spp. included in StreptomeDB. (a) Enduracidin A, NRPS-derived antibiotic; (b) daunorubicin,
antitumour anthracycline; (c) oxytetracycline, tetracycline antibiotic; (d) bleomycin, NRPS/PKS-derived anticancer; (e) geldanamycin, macro-cyclic
Hsp90 inhibitor; (f) epothilone B, anticancer macro-cycle; (g) fredericamycin A, C-5 spirocyclic DNA-polymerase inhibitor; (h) chloramphenicol,
broad-spectrum antibiotic; (i) tacrolimus, macro-cyclic immunosuppressive; (j) fosfomycin, broad-spectrum antibiotic; (k) geranylphenazinediol,
acetyl-CoA inhibitor; (l) actinomycin, NRPS/PKS-derived antineoplastic agent and (m) daptomycin, NRPS-derived antibiotic.










synthesis would be of interest for the research community.
Even though most of this information is not yet described
in the literature, the inclusion of the available data will be
part of StreptomeDB in future updates.
We provide the complete dataset for download
including the structural information. This opens the pos-
sibility for modelling molecular interactions on the struc-
tural level. In silico screening approaches for the
Figure 2. MCSS panel in StreptomeDB, featuring the most common cyclic structures included in the database.
Figure 3. Workﬂow of a substructure search for arizidine-containing compounds in StreptomeDB.










identiﬁcation of new drugs are becoming more and more
important (38–40). We believe that the presented dataset is
a valuable molecular library for the virtual screening of
therapeutically important target proteins. For many NPs,
the complete activity spectrum is not clariﬁed yet. The
supplied data will help identifying NPs or analogues
useful as candidates of new active compounds.
CONCLUSION
To the best of our knowledge, StreptomeDB is the largest
database describing NPs produced by streptomycetes.
Downloadable chemical structures allow for the applica-
tion in virtual screening. Collected data will support
analyses of gene clusters and associated enzymes respon-
sible for the synthesis of functional groups. Streptomyces
is the most important genus for the production of thera-
peutic NPs. Thus, the database will be of interest for re-
searchers working in the area of drug discovery and
chemistry.
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